Evaluation of a Multiplex Fully Automated Treponemal and Nontreponemal (Rapid Plasma Reagin) Assay

Research output: Contribution to journalArticle

Abstract

OBJECTIVES: In June 2017, Bio-Rad Laboratories received US Food and Drug Administration clearance for its BioPlex 2200 Syphilis Total & RPR (rapid plasma reagin) assay. It is the first fully automated treponemal/nontreponemal multiplex flow immunoassay, simultaneously detecting Treponema pallidum and reagin antibodies and an RPR titer. We compared the performance of the BioPlex Syphilis Total & RPR assay with the LIAISON Treponema Assay and the manual BD Macro-Vue RPR 18-mm Circle Test. METHODS: In total, 314 serum specimens were tested for treponemal immunoglobulin G/immunoglobulin M and RPR with the LIAISON Treponema Assay, the BioPlex 2200 Syphilis Total & RPR assay, and the manual BD Macro-Vue RPR card test. All discordant results were further tested with the T pallidum particle agglutination assay from Fujirebio Diagnostics. RESULTS: The overall percent agreement for the BioPlex assay for treponemal antibodies with the LIAISON Treponema Assay was 96.1%. Sensitivity and specificity for the BioPlex RPR assay were 90.5% and 97.2%, respectively (the manual RPR assay was considered the gold standard). CONCLUSIONS: The BioPlex 2200 Syphilis Total & RPR assay performance was comparable to the LIAISON Treponema Assay and the manual RPR test. Compared with the manual RPR, the automation of RPR testing offered labor savings, objective result reporting, and improved workflow.

Original languageEnglish (US)
Pages (from-to)230-236
Number of pages7
JournalAmerican journal of clinical pathology
Volume152
Issue number2
DOIs
StatePublished - Jul 5 2019

Fingerprint

Reagins
Treponema
Syphilis
Treponema pallidum
Globus Pallidus
Workflow
Antibodies
Automation
Agglutination
United States Food and Drug Administration

Keywords

  • Automation
  • Rapid plasma reagin (RPR)
  • Syphilis antibody testing

PubMed: MeSH publication types

  • Journal Article

Cite this

Evaluation of a Multiplex Fully Automated Treponemal and Nontreponemal (Rapid Plasma Reagin) Assay. / Arbefeville, Sophie S; Lynch, Maureen; Ferrieri, Patricia.

In: American journal of clinical pathology, Vol. 152, No. 2, 05.07.2019, p. 230-236.

Research output: Contribution to journalArticle

@article{71b5d327a0b2498fb0e62b57475c8da1,
title = "Evaluation of a Multiplex Fully Automated Treponemal and Nontreponemal (Rapid Plasma Reagin) Assay",
abstract = "OBJECTIVES: In June 2017, Bio-Rad Laboratories received US Food and Drug Administration clearance for its BioPlex 2200 Syphilis Total & RPR (rapid plasma reagin) assay. It is the first fully automated treponemal/nontreponemal multiplex flow immunoassay, simultaneously detecting Treponema pallidum and reagin antibodies and an RPR titer. We compared the performance of the BioPlex Syphilis Total & RPR assay with the LIAISON Treponema Assay and the manual BD Macro-Vue RPR 18-mm Circle Test. METHODS: In total, 314 serum specimens were tested for treponemal immunoglobulin G/immunoglobulin M and RPR with the LIAISON Treponema Assay, the BioPlex 2200 Syphilis Total & RPR assay, and the manual BD Macro-Vue RPR card test. All discordant results were further tested with the T pallidum particle agglutination assay from Fujirebio Diagnostics. RESULTS: The overall percent agreement for the BioPlex assay for treponemal antibodies with the LIAISON Treponema Assay was 96.1{\%}. Sensitivity and specificity for the BioPlex RPR assay were 90.5{\%} and 97.2{\%}, respectively (the manual RPR assay was considered the gold standard). CONCLUSIONS: The BioPlex 2200 Syphilis Total & RPR assay performance was comparable to the LIAISON Treponema Assay and the manual RPR test. Compared with the manual RPR, the automation of RPR testing offered labor savings, objective result reporting, and improved workflow.",
keywords = "Automation, Rapid plasma reagin (RPR), Syphilis antibody testing",
author = "Arbefeville, {Sophie S} and Maureen Lynch and Patricia Ferrieri",
year = "2019",
month = "7",
day = "5",
doi = "10.1093/ajcp/aqz034",
language = "English (US)",
volume = "152",
pages = "230--236",
journal = "American Journal of Clinical Pathology",
issn = "0002-9173",
publisher = "American Society of Clinical Pathologists",
number = "2",

}

TY - JOUR

T1 - Evaluation of a Multiplex Fully Automated Treponemal and Nontreponemal (Rapid Plasma Reagin) Assay

AU - Arbefeville, Sophie S

AU - Lynch, Maureen

AU - Ferrieri, Patricia

PY - 2019/7/5

Y1 - 2019/7/5

N2 - OBJECTIVES: In June 2017, Bio-Rad Laboratories received US Food and Drug Administration clearance for its BioPlex 2200 Syphilis Total & RPR (rapid plasma reagin) assay. It is the first fully automated treponemal/nontreponemal multiplex flow immunoassay, simultaneously detecting Treponema pallidum and reagin antibodies and an RPR titer. We compared the performance of the BioPlex Syphilis Total & RPR assay with the LIAISON Treponema Assay and the manual BD Macro-Vue RPR 18-mm Circle Test. METHODS: In total, 314 serum specimens were tested for treponemal immunoglobulin G/immunoglobulin M and RPR with the LIAISON Treponema Assay, the BioPlex 2200 Syphilis Total & RPR assay, and the manual BD Macro-Vue RPR card test. All discordant results were further tested with the T pallidum particle agglutination assay from Fujirebio Diagnostics. RESULTS: The overall percent agreement for the BioPlex assay for treponemal antibodies with the LIAISON Treponema Assay was 96.1%. Sensitivity and specificity for the BioPlex RPR assay were 90.5% and 97.2%, respectively (the manual RPR assay was considered the gold standard). CONCLUSIONS: The BioPlex 2200 Syphilis Total & RPR assay performance was comparable to the LIAISON Treponema Assay and the manual RPR test. Compared with the manual RPR, the automation of RPR testing offered labor savings, objective result reporting, and improved workflow.

AB - OBJECTIVES: In June 2017, Bio-Rad Laboratories received US Food and Drug Administration clearance for its BioPlex 2200 Syphilis Total & RPR (rapid plasma reagin) assay. It is the first fully automated treponemal/nontreponemal multiplex flow immunoassay, simultaneously detecting Treponema pallidum and reagin antibodies and an RPR titer. We compared the performance of the BioPlex Syphilis Total & RPR assay with the LIAISON Treponema Assay and the manual BD Macro-Vue RPR 18-mm Circle Test. METHODS: In total, 314 serum specimens were tested for treponemal immunoglobulin G/immunoglobulin M and RPR with the LIAISON Treponema Assay, the BioPlex 2200 Syphilis Total & RPR assay, and the manual BD Macro-Vue RPR card test. All discordant results were further tested with the T pallidum particle agglutination assay from Fujirebio Diagnostics. RESULTS: The overall percent agreement for the BioPlex assay for treponemal antibodies with the LIAISON Treponema Assay was 96.1%. Sensitivity and specificity for the BioPlex RPR assay were 90.5% and 97.2%, respectively (the manual RPR assay was considered the gold standard). CONCLUSIONS: The BioPlex 2200 Syphilis Total & RPR assay performance was comparable to the LIAISON Treponema Assay and the manual RPR test. Compared with the manual RPR, the automation of RPR testing offered labor savings, objective result reporting, and improved workflow.

KW - Automation

KW - Rapid plasma reagin (RPR)

KW - Syphilis antibody testing

UR - http://www.scopus.com/inward/record.url?scp=85069274577&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85069274577&partnerID=8YFLogxK

U2 - 10.1093/ajcp/aqz034

DO - 10.1093/ajcp/aqz034

M3 - Article

C2 - 31139835

AN - SCOPUS:85069274577

VL - 152

SP - 230

EP - 236

JO - American Journal of Clinical Pathology

JF - American Journal of Clinical Pathology

SN - 0002-9173

IS - 2

ER -